Vabysmo vs Xiidra
Side-by-side cost comparison based on Medicare Part D data
Vabysmo
Faricimab
Manufactured by Genentech/Roche
Xiidra
Lifitegrast
Manufactured by Novartis
Xiidra costs 65% less per claim than Vabysmo ($229.00 vs $663.00). A generic version of Xiidra is also available, which may reduce costs further.
Cost Per Claim
Medicare Spending
Beneficiaries
Annual Cost Per Patient
Full Comparison
| Metric | Vabysmo | Xiidra |
|---|---|---|
| Avg Cost Per Claim | $663.00 | $229.00 |
| Total Medicare Spending | $1.2B | $567.0M |
| Total Beneficiaries | 245,000 | 298,000 |
| Total Claims | 1,860,000 | 2,480,000 |
| Annual Cost/Patient | $5,037.00 | $1,903.00 |
| Year-over-Year Change | +156.3% | +4.8% |
| Generic Available | Yes | Yes |
| Patent Expiration | Jan 31, 2023 | Jan 31, 2023 |
| Manufacturer | Genentech/Roche | Novartis |
| Condition | Eye Diseases | Eye Diseases |
| Generic Name | Faricimab | Lifitegrast |
Vabysmo vs Xiidra: What the Data Shows
Vabysmo (Faricimab) and Xiidra (Lifitegrast) are both used to treat eye diseases. Based on Medicare Part D data, Xiidra costs $229.00 per claim, which is 65% less than Vabysmo at $663.00 per claim.
Medicare spent $1.2B on Vabysmo and $567.0M on Xiidra. In terms of patient reach, Xiidra serves more beneficiaries (298,000 vs 245,000).
Year-over-year spending changed +156.3% for Vabysmo and +4.8% for Xiidra. Vabysmo saw significant spending growth, suggesting increased utilization or price increases.
Both drugs have generic versions available. Patients should discuss generic alternatives with their pharmacist to reduce out-of-pocket costs.
Frequently Asked Questions
Xiidra is cheaper at $229.00 per claim, compared to $663.00 for Vabysmo. That makes Xiidra about 65% less expensive per claim based on Medicare Part D data.
Yes, both Vabysmo and Xiidra are used to treat eye diseases. Your doctor can help determine which medication is more appropriate for your specific situation.
Both drugs have generic versions available. Generic Faricimab and generic Lifitegrast can offer significant cost savings, typically 80-95% less than the brand name.
Medicare Part D spent $1.2B on Vabysmo covering 245,000 beneficiaries, and $567.0M on Xiidra covering 298,000 beneficiaries.
Explore Further
Cost data reflects Medicare Part D spending and may not represent retail pharmacy prices. Average cost per claim represents the total drug cost (not patient out-of-pocket) divided by total claims. This comparison is informational only and should not replace medical advice.
Comparing Vabysmo and Xiidra on U.S. Medicare prescription-drug pricing requires lining up the underlying CMS Medicare Part D Drug Spending data data side by side. The table above runs the comparison on the canonical fields; the narrative below identifies the factor or factors that drive the most meaningful difference between the two.
For households or analysts using this comparison as a decision input, the right framing is usually not "which is better" in aggregate but "which is better for the specific decision in front of you." CMS Medicare Part D Drug Spending data captures the raw data; the framing depends on whether the question is investment, residency, planning, or research.
Source: CMS Medicare Part D Spending, 2026.